9MW5211 is a highly specific depleting innovative antibody independently developed by Mabwell, designed to precisely intervene in the key pathological mechanisms mediated by abnormal immune cells in autoimmune diseases. The abnormal activation and tissue infiltration of immune cells are core driving factors in the onset and progression of various autoimmune diseases. The molecule targeted by 9MW5211 is specifically expressed on the surface of pathogenic immune cells and serves as an important biological marker of their abnormal activation. By selectively recognizing and depleting these pathogenic cells, 9MW5211 can effectively block the immune cascade response, thereby alleviating disease progression and improving clinical symptoms.
Through multiple rounds of molecular engineering optimization, 9MW5211 demonstrates excellent target selectivity, achieving efficient blockade while significantly reducing the risk of non-specific binding, ensuring deep depletion of pathogenic cells with high target protein expression. Its unique mechanism of action not only holds the potential for deeper disease remission but may also support longer dosing intervals, thereby enhancing patient treatment compliance and quality of life.
Preclinical study results show that 9MW5211 exhibits significant therapeutic potential in various mouse models of autoimmune diseases, with future clinical applications expected to cover multiple major indications. Safety assessments conducted in cynomolgus monkey models indicate a favorable safety profile. Clinical trial applications for other indications are currently in progress.
About Inflammatory Bowel Disease (IBD)
Inflammatory bowel disease is a chronic, relapsing, immune-mediated gastrointestinal disorder, primarily including ulcerative colitis and Crohn’s disease. The global number of IBD cases is steadily increasing. Epidemiological studies show that the number of new IBD patients worldwide rose from 5.9 million in 2019 to 7.0 million in 2023, with a compound annual growth rate of 4.4%. It is estimated that the number of new IBD patients globally will reach 11.5 million by 2032, with a compound annual growth rate of 5.6% from 2023 to 2032.
About Multiple Sclerosis (MS)
Multiple sclerosis is a chronic autoimmune disease in which inflammatory responses damage the protective myelin sheath surrounding nerves in the brain and spinal cord. The global number of MS patients increased from 2.8 million in 2020 to 3.0 million in 2024, and is expected to reach approximately 3.5 million by 2035. The number of MS patients in China grew from 32,800 in 2020 to 33,900 in 2024, and is projected to reach 35,500 by 2035.
About Mabwell
Mabwell (688062.SH, 02493.HK) is an innovative biopharmaceutical company with a full industry chain layout. Always adhering to the vision of “Turning Innovation into Reality” and the mission of “Exploring Life, Benefiting Health,” we provide patients with better efficacy and more accessible innovative biologics through original innovation to meet unmet clinical needs worldwide. Since its establishment in 2017, Mabwell has built an innovation system covering the entire drug R&D cycle, starting from antibody drug target discovery and molecule discovery, through druggability research, preclinical research, clinical research, and production transformation, achieving a full industry chain layout integrating R&D, production, and marketing. We focus on oncology and age-related diseases, involving therapeutic areas such as oncology, autoimmune diseases, bone diseases, ophthalmology, hematology, and cardiovascular diseases. Leveraging internationally leading proprietary technology platforms and R&D innovation capabilities, we have established a rich and competitive pipeline. Currently, we have 15 key products in preclinical, clinical, or marketing stages, including 11 innovative products and 4 biosimilars, of which 4 products are on the market, 1 product is under marketing review, and 2 products are in Phase III pivotal registration clinical trials. We independently undertake 1 national “Major New Drug Creation” major science and technology project, 2 national key R&D programs, and multiple provincial and municipal science and technology innovation projects. Mabwell is innovation-oriented and emphasizes industrial transformation. Our antibody and recombinant protein drug industrialization base, compliant with China NMPA, US FDA, and EU EMA GMP standards, has been put into operation in Taizhou, Jiangsu, and has passed the EU QP audit. Large-scale commercial production bases in Jinshan, Shanghai, and Taizhou, Jiangsu, are under construction. For more information, please visit: www.mabwell.com.
Forward-Looking Statements
The information released in this press release may contain certain forward-looking statements. These statements are inherently subject to significant risks and uncertainties. When using words such as “anticipate,” “believe,” “predict,” “expect,” “intend,” and other similar expressions, any reference to the Company is intended to identify such statements as forward-looking. The Company is under no obligation to continuously update these forward-looking statements.
These forward-looking statements are based on the current views, assumptions, expectations, estimates, predictions, and understandings of the Company’s management regarding future events at the time the statements are made. These statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond the Company’s control and difficult to predict. Therefore, actual results may differ materially from the information contained in the forward-looking statements due to future changes and developments in our business, competitive environment, and political, economic, legal, and social conditions.
The Company, its directors, and employees and agents assume no obligation to (a) correct or update any forward-looking statements contained on this website; and (b) assume any liability arising from the failure of any forward-looking statement to materialize or becoming incorrect.